制度・支援
指定難病 — No.178

モワット・ウィルソン症候群

検索語 Mowat-Wilson Syndrome ・ 最終更新 2026-07-21 17:32 ・ 最新に更新

Data Sheet
指定 No.178
Src PubMed · CT.gov · jRCT

これは医療アドバイスではありません。診断・治療の判断は必ず主治医にご相談ください。論文や治験は「今わかっている研究の状況」を示すもので、効果を保証するものではありません。

( 01 )EVIDENCE / PUBMED · 4件

世界の論文

直近の研究を、やさしい日本語で

各論文の見出しにある「確からしさ」は、その研究がどれくらい信頼できるかの目安です。「理論段階」はまだ仮説に近く、下にいくほど多くの患者で検証されていて、「メタ解析」がもっとも信頼できます。

不明
MK-01 · PMID 42396398

Leveraging Next-Generation Phenotyping in Dysmorphology to Support Variant Interpretation in Mowat-Wilson Syndrome

Abstract / 原文

BACKGROUND AND OBJECTIVES: Next-generation phenotyping (NGP) tools, such as GestaltMatcher, have revolutionized the diagnosis of rare genetic disorders through computational facial analysis. While NGP has been widely integrated into differential diagnosis workflows, its application in variant reclassification within the ACMG framework remains underexplored. METHODS: We applied GestaltMatcher to a 4-year-old patient with an undiagnosed neurodevelopmental disorder, suspected Mowat-Wilson syndrome (MWS), and a de novo ZEB2 variant. In addition to facial image analysis, we used the PEDIA framework, integrating Human Phenotype Ontology (HPO) terms and simulated exome data to refine variant prioritization. Bayesian likelihood modeling was used to establish Gestalt score thresholds for PP4 evidence levels (supporting, moderate, strong, and very strong). Brain MRI analysis was also performed to assess structural abnormalities characteristic of MWS. RESULTS: GestaltMatcher ranked MWS as the top differential diagnosis, and PEDIA integration further confirmed ZEB2 as the most likely disease-causing gene. Three of the patient's 4 facial images met the PP4 moderate threshold, while one met PP4 supporting. MRI analysis revealed subtle corpus callosum thinning, consistent with MWS. In addition, an exploratory case of an infant with molecularly confirmed MWS demonstrated the capability of GestaltMatcher to prioritize the diagnosis solely based on infant facial features. DISCUSSION: This study highlights the potential of NGP-driven facial phenotyping and multimodal integration in dysmorphology. The results support the broader application of AI-assisted phenotyping to improve diagnostic accuracy, particularly in neurodevelopmental disorders with distinct facial features.

Journal
Neurology. Genetics(2026 Aug)
Authors
14名
Type
Journal Article
PubMedで原文を見る
症例報告
MK-02 · PMID 42289242

Cutis Tricolor-Like Pigmentary Mosaicism in Mowat-Wilson Syndrome: Phenotypic Overlap With Ruggieri-Happle Syndrome

Abstract / 原文

Cutis tricolor (CT) is a rare pigmentary mosaicism characterized by the coexistence of hyperpigmented and hypopigmented areas on a background of normal skin; its syndromic form, Ruggieri-Happle syndrome (RHS), is associated with neurodevelopmental delay, facial dysmorphism, skeletal abnormalities, and other systemic defects. We report a 16-year-old girl with molecularly confirmed Mowat-Wilson syndrome caused by a de novo pathogenic ZEB2 frameshift variant, who presented with extensive CT-like pigmentary mosaicism and marked phenotypic overlap with RHS. Brain MRI disclosed bilateral microphthalmia, optic nerve hypoplasia, coloboma, a shortened corpus callosum, a brainstem segmentation defect, and inferior vermian hypoplasia. This observation expands the cutaneous phenotype of ZEB2-related disease and suggests possible shared developmental pathways between Mowat-Wilson syndrome and RHS.

Journal
Pediatric dermatology(2026 Jun)
Authors
3名
Type
Case Reports, Journal Article
PubMedで原文を見る
観察研究
MK-03 · PMID 42184404

Hirschsprung's disease and Mowat-Wilson syndrome: should a pull-through be performed?

Abstract / 原文

BACKGROUND: Hirschsprung's disease (HSCR) is characterized by the absence of ganglion cells. Five percent of cases are associated with syndromic conditions, one of which is Mowat-Wilson syndrome (MWS), with an incidence rate of 50%. HSCR may be the first feature of this syndrome to be diagnosed. MWS is an autosomal dominant genetic disorder caused by a variant in the ZEB2 gene (ZFHX1B). OMIM #235730. It involves severe clinical manifestations such as ocular hypertelorism, intellectual disability, congenital heart defects, epilepsy, and HSCR. The association between MWS and HSCR is regarded as a serious condition with unpredictable post-operative outcomes, and many reported complications related to motility disorders are noted. METHODS: We conducted a retrospective study and reviewed the medical records of patients with MWS treated at our center. We examined the relationship among HSCR, clinical features, molecular characteristics, surgical complications, and pre-operative and post-operative enterocolitis events. RESULTS: The study included four patients with MWS. Three (75%) were found to be associated with HSCR. Rectal biopsy confirmed HSCR in all patients. Two patients underwent a transanal pull-through Swenson procedure, and both experienced surgical complications. Both cases encountered multiple episodes of enterocolitis, and one of them required a permanent stoma. The third patient has not undergone surgical correction but has responded well to medical treatment (laxatives). CONCLUSIONS: The association between MWS and HSCR presents a severe condition with high morbidity. The outcome after the pull-through procedure is unpredictable. Further studies are necessary to gain a deeper understanding of this condition. We recommend evaluating these patients in a multidisciplinary consensus based on the existing literature and our findings. Those without recurrent enterocolitis or chronic motility disorders are suitable candidates for conservative management.

Journal
Boletin medico del Hospital Infantil de Mexico(2026)
Authors
8名
Type
Journal Article
PubMedで原文を見る
観察研究
MK-04 · PMID 42038223

Gastrointestinal dysfunction in patients with Mowat-Wilson syndrome is associated with feeding difficulties and altered plasma neurotransmitters

Abstract / 原文

BACKGROUND: Intestinal dysfunction is prevalent in children with Mowat-Wilson syndrome (MWS), yet its underlying mechanisms remain unclear. This study aimed to characterize intestinal symptoms, feeding patterns, and fasting plasma neurotransmitter profiles in patients with MWS, and to explore their potential relationships. METHODS: Three complementary assessments were conducted, including a questionnaire assessing defecation difficulties and stool characteristics; a structured questionnaire assessing feeding difficulties, caregiver-reported dietary composition (including the proportion of meat), and complementary feeding practices; and targeted fasting plasma neurotransmitter profiling using UPLC-TQ-MS. RESULTS: Among 35 patients with MWS, 86% had intestinal symptoms, including constipation (69%) and Hirschsprung disease (17%). In the feeding/diet analysis, 44.4% (4/9) of patients with MWS reported feeding difficulties. Compared with age-matched healthy controls (n = 10), patients with MWS (n = 9) had a significantly lower proportion of meat and delayed introduction of meat-based complementary foods (10.5 months vs. 7.9 months). In the plasma analysis, patients with MWS (n = 6) exhibited significantly reduced plasma levels of serotonin and taurine, alongside elevated levels of GABA and dopamine, compared with age-matched healthy controls (n = 10). CONCLUSION: These findings confirm the high prevalence of constipation-predominant intestinal dysfunction in patients with MWS. Collectively, our findings support further investigation of associations among feeding difficulties, a lower proportion of meat in dietary composition, and an altered fasting plasma neurotransmitter profile (including lower serotonin in a small subset), which may be relevant to gut dysmotility in patients with MWS. This diet-neurotransmitter axis offers a working model for understanding intestinal dysfunction in patients with MWS, yet direct quantification of dietary and circulating tryptophan in future studies is needed to validate this pathway.

Journal
Frontiers in pediatrics(2026)
Authors
9名
Type
Journal Article
PubMedで原文を見る
( 02 )TRIALS / JAPAN · 0件

日本で参加できる治験

現在 募集中のもの

日本で現在募集中の治験は見つかりませんでした。下の公式レジストリで条件を変えると見つかる場合があります。
( 03 )REGISTRY / jRCT

治験をもっと探す

日本の公式レジストリで全件を確認

上の一覧は ClinicalTrials.gov の一部です。日本国内の治験の多くは、日本の公式レジストリ jRCT にのみ登録されています。下記から最新の全件をご確認ください。

※ jRCTは自動の大量データ取得を禁じているため、本サービスはjRCTを自動収集せず、患者ご自身が公式サイトで検索できるリンクでご案内しています(規約順守)。

お金・介護・制度モワット・ウィルソン症候群の療養に使えるかもしれない公的サポートを調べる医療費・生活費・介護の支援制度と相談先を、あなたの状況に合わせてご案内(回答は端末内で完結)
( 04 )SUPPORT

患者会・相談窓口

一人で抱え込まないでください

同じ病気の患者・家族とつながる、制度や生活の相談をする、といったときの窓口です。

全国の相談先

※ お住まいの都道府県の「難病相談支援センター」でも、医療費助成や療養生活の相談ができます(難病情報センターから探せます)。